PHARMA NEWS

PHARMA NEWS :- Pharmatimes

Sitryx reports phase 1b data for SYX-5219 October 22, 2026
Results support advancement into phase 2 trials
John Pinching
ViiV and Axmed expand access to HIV medicines October 22, 2026
Agreement enables procurement in over 50 countries
John Pinching
Osivax reports phase 2b data for OVX836 October 21, 2026
Results support combination strategy for influenza vaccines
John Pinching
Merz completes phase 3 recruitment for XEOMIN October 21, 2026
Global trials assess migraine prevention potential
John Pinching
CHMP backs TALVEY plus daratumumab for earlier myeloma use October 20, 2026
Recommendation supports second-line combination option
John Pinching
CHMP backs RASONQUE for metastatic pancreatic cancer October 20, 2026
Positive opinion supports EU marketing authorisation
John Pinching
Libtayo dosing backed by CHMP October 19, 2026
Regimen update recommended across all indications
John Pinching
Sanofi breaks ground on new insulin facility October 19, 2026
New Frankfurt site to boost long-term supply
John Pinching
RougeTx launches with $58 million series A financing for HHT therapy October 15, 2026
New company to advance first‑in‑class treatment
John Pinching
Lundbeck presents phase 1b data for Lu AF28996 in advanced Parkinson’s disease October 15, 2026
Phase 2 development underway as DARE2 trial begins
John Pinching

PHARMA NEWS :- Pharma Voice

A cancer drug worked in the lab — but not how scientists thought October 23, 2026
Researchers uncovered the unexpected mechanism behind a cancer drug candidate, highlighting a persistent problem in drug discovery.
Kelly Bilodeau
Most new drugs are still too costly at launch, ICER says October 22, 2026
A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.
Jonathan Gardner
Drug discovery is speeding up. But clinical trials are buckling under their own weight. October 22, 2026
A growing pipeline is colliding with tougher recruitment, more demanding protocols and trial operations struggling to keep pace — and AI alone can’t fix it.
Sy Mukherjee
A CEO, an ex-CDC director and an ex-FDA commissioner walk into a biotech… October 21, 2026
Dr. Robert Redfield and Dr. Stephen Hahn came aboard Turn Therapeutics this year to help the clinical-stage company develop a platform that could one day change how vaccines are delivered.
Kelly Bilodeau
Pharma gift giving linked to writing more prescriptions — but less appropriate prescribing October 20, 2026
The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors prescribe, according to a new analysis.
Alexandra Pecci
Biotech is booming — and startups are still dying October 19, 2026
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs to the brink.
Meagan Parrish
Alzheimer’s trials need patients. Why are so many screened out? October 16, 2026
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing safety.
Kelly Bilodeau
FDA ‘reset’ continues with new plan for reviewing rare disease drugs October 16, 2026
A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.
Kristin Jensen
Hype vs. reality: What pharma’s hottest R&D bets have actually proved October 15, 2026
New types of bispecifics, ADCs and CAR-Ts are still proving themselves in the clinic — pharma’s betting billions anyway.
Sy Mukherjee
A new startup takes aim at a suspected culprit in autoimmune disease October 14, 2026
Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune conditions: diseased T cells.
Kelly Bilodeau

Sitryx reports phase 1b data for SYX-5219
Results support advancement into phase 2 trials
ViiV and Axmed expand access to HIV medicines
Agreement enables procurement in over 50 countries
Osivax reports phase 2b data for OVX836
Results support combination strategy for influenza vaccines
Merz completes phase 3 recruitment for XEOMIN
Global trials assess migraine prevention potential
CHMP backs TALVEY plus daratumumab for earlier myeloma use
Recommendation supports second-line combination option
CHMP backs RASONQUE for metastatic pancreatic cancer
Positive opinion supports EU marketing authorisation
Libtayo dosing backed by CHMP
Regimen update recommended across all indications
Sanofi breaks ground on new insulin facility
New Frankfurt site to boost long-term supply
RougeTx launches with $58 million series A financing for HHT therapy
New company to advance first‑in‑class treatment
Lundbeck presents phase 1b data for Lu AF28996 in advanced Parkinson’s disease
Phase 2 development underway as DARE2 trial begins

GMP and Quality

Non-conformances in Pharmaceutical Laboratories

Pharma VedMay 8, 2024

Pharmaceutical quality control laboratories are the guardians of public health. Through meticulous testing of raw materials, in-process materials, and finished products, they ensure the safety and efficacy of medications. However, nonconformances can arise...